D. E. Shaw & Co., Inc. Clovis Oncology, Inc. Put Options Transaction History

D. E. Shaw & Co., Inc.

7 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2019 Nov 14, 2019	BUY	$3.93 - $15.35 $344,268 - $1.34 Million	87,600 Added 706.45%	100,000 $393,000
Q1 2019 May 15, 2019	SELL	$17.66 - $30.28 $268,432 - $460,256	-15,200 Reduced 55.07%	12,400 $308,000
Q4 2018 Feb 14, 2019	BUY	$11.63 - $32.67 $82,573 - $231,957	7,100 Added 34.63%	27,600 $496,000
Q2 2018 Aug 14, 2018	SELL	$42.06 - $62.4 $609,870 - $904,800	-14,500 Reduced 41.43%	20,500 $932,000
Q1 2018 May 15, 2018	SELL	$50.12 - $67.72 $185,444 - $250,564	-3,700 Reduced 9.56%	35,000 $1.85 Million
Q4 2017 Feb 14, 2018	BUY	$57.69 - $84.58 $501,903 - $735,846	8,700 Added 29.0%	38,700 $2.63 Million
Q3 2017 Nov 14, 2017	BUY	$67.17 - $84.81 $2.02 Million - $2.54 Million	30,000	30,000 $2.47 Million

166

Ticker CLVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 144,480,000
Market Cap $13M
Description
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or pr...

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.